29th week of 2022 patent applcation highlights part 23 |
Patent application number | Title | Published |
20220227765 | PYRIDO-INDOLE ANALOGUES AS GPX4 INHIBITORS - This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent. | 2022-07-21 |
20220227766 | PREPARATION METHOD FOR (R)-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXYLIC ACID, DERIVATIVES THEREOF AND LEVO-PRAZIQUANTEL - Preparation method for a compound as shown in formula (I) and levo-praziquantel. A racemate of ester of the compound of formula (I) is used as a substrate, and reaction is performed under the catalysis of immobilized lipase to produce the compound of formula (I); a circulating fluidized bed reactor is used, the circulating fluidized bed reactor includes an external circulation system and a reaction column, the immobilized lipase is arranged in the reaction column, the substrate solution is circulated many times between the external circulation system and the reaction column, the reaction is performed in the reaction column. The preparation of levo-praziquantel includes the described preparation steps of the formula (I). The preparation method of formula (I) can significantly improve the utilization rate of enzyme and reduce the use ratio of enzyme/substrate, and has mild reaction conditions, strong stereoselectivity, high reaction efficiency. | 2022-07-21 |
20220227767 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE - Described herein are heterocyclic compounds, compositions, and methods for their use for the treatment of disease. | 2022-07-21 |
20220227768 | CHEMICAL COMPOUNDS - The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine. | 2022-07-21 |
20220227769 | CRYSTALLINE FORM OF TELMAPITANT OR (5R,8S)-8-[[(1R)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY]METHYL]-8-PHENY- L-1,3,7-TRIAZASPIRO[4.5]DECANE-2,4-DIONE - The present disclosure encompasses a crystalline form of (5R,8S)-8-[[(1R)-1-[3,5bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione and processes for the preparation thereof. | 2022-07-21 |
20220227770 | SALTS OF TAM INHIBITORS - The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto. | 2022-07-21 |
20220227771 | ANDROGEN RECEPTOR BINDING MOLECULE AND USE THEREOF - An androgen receptor (AR) binding molecule has the structure of Formula (I) shown in the following: | 2022-07-21 |
20220227772 | DEUTERATED TRIAZOLOPYRIMIDINES - The present disclosure provides compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R | 2022-07-21 |
20220227773 | FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention relates to a fused ring compound represented by general formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and use thereof. The compound provided in the present invention is useful for treating, preventing and/or controlling various nervous system disorders. The compound provided in the present invention modulates one or more monoamine transporters, inhibits the reuptake of endogenous monoamines such as dopamine, 5-hydroxytryptamine, and norepinephrine (e.g., from the synaptic cleft), and/or modulates the 5-HT | 2022-07-21 |
20220227774 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS - The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R | 2022-07-21 |
20220227775 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR - A 1H-pyrazolo[4,3-H]quinazoline compound represented by formula (I) can be used for treating cell proliferation dysfunction, and is an broad-spectrum and strongly-active inhibitor for a cell cyclin-dependent kinase (CDK). | 2022-07-21 |
20220227776 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT - The present invention provides novel compounds and pharmaceutically acceptable salts or esters thereof. For example, the compound has the structure of Formula V. Also provided is a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier. Further provided a method for inhibiting a polymerase of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (SARS-CoV-2 polymerase) or treating viral infection in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition to the subject, for example, orally. | 2022-07-21 |
20220227777 | SYNTHESIS METHOD OF FUROIMIDAZOPYRIDINE COMPOUND, CRYSTAL FORM OF FUROIMIDAZOPYRIDINE COMPOUND, AND CRYSTAL FORM OF SALT THEREOF - Provided is a method for synthesizing a compound 2-[(2R,5S)-5-[2-[(R)-1-hydroxyethyl]furo[3,2-b]imidazo[4,5-d]pyridin-1-yl]tetrahydropyran-2-yl]acetonitrile as a selective JAK1/TYK2 kinase inhibitor. The compound is prepared by nucleophilic substitution, palladium on carbon reduction, and cyclization reaction using 7-chloro-6-nitrofuro[3,2-b]pyridine as a starting material. The synthesis method has mild reaction conditions, high product yield, and high purity, and is suitable for industrial production. Further provided are a crystal form of the compound, crystal forma of its salts, and their preparation methods. The crystal form of the compound and the crystal forms of its salts have good physical and chemical properties and are suitable for drug development. | 2022-07-21 |
20220227778 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF - The present disclosure provides compounds represented by Formula I: | 2022-07-21 |
20220227779 | METHOD FOR PREPARING DIHYDROARTEMISININ BULK DRUG IN SINGLE PROCESS - A method for preparing dihydroartemisinin bulk drug in single process comprises: S1. dissolving artemisinin in aprotic solvent; S2. adding phase transfer catalyst and reducing agent in sequence to cause a reduction reaction with artemisinin; S3. adjusting the pH of the reaction system obtained in step S2 to 5-7 with acid solution, adding water and stirring, separating the liquids, extracting the aqueous phase obtained by the separation with the same aprotic solvent as in step S1, combining the organic phase obtained by extraction and separation, washing with water, and drying, obtaining dried organic phase; S4. placing the dried organic phase obtained in step S3 in a crystallization device that has the functions of crystallization-press filtration-drying, and then the crystals are precipitated, concentrated, press-filtered, and dried to obtain the refined dihydroartemisinin. | 2022-07-21 |
20220227780 | DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS - Compounds are provided having Formula (I): | 2022-07-21 |
20220227781 | PYRIMIDINE DERIVATIVE INHIBITING GROWTH OF CANCER CELL AND MEDICINAL USE THEREOF - The present invention provides novel pyrimidine derivative compounds inhibiting growth of cancer cells and pharmaceutically acceptable salts thereof. The present invention provides a pharmaceutical composition comprising these compounds or pharmaceutically acceptable salts. The present invention also provides a medical use for treatment of lung cancer, characterized by using these pyrimidine derivative compounds and pharmaceutically acceptable salts thereof as an active ingredient. The present invention also provides a method for treatment of lung cancer comprising administering an effective dose of compounds according to the present invention, salts thereof or a composition comprising them. | 2022-07-21 |
20220227782 | COMPOUND FOR INHIBITING RORyt ACTIVITY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - The present invention relates to a compound for inhibiting RORγt activity, a preparation method therefor and an application thereof. The compound for inhibiting RORγt activity has the following structural formula (A): | 2022-07-21 |
20220227783 | ORGANIC ELECTRO-OPTIC CHROMOPHORES - Chromophores with large hyperpolarizabilities, films with electro-optic activity comprising the chromophores, and electro-optic devices comprising the chromophores are disclosed. | 2022-07-21 |
20220227784 | SOLID STATE FORMS OF RELUGOLIX - The present disclosure provides solid state forms of Relugolix, crystalline forms of Relugolix, pharmaceutical compositions thereof, and pharmaceutical formulations thereof. Methods for producing these forms of Relugolix, pharmaceutical compositions, and pharmaceutical formulations are also provided. | 2022-07-21 |
20220227785 | NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) - The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds. | 2022-07-21 |
20220227786 | Spiro Bicyclic Inhibitors Of Menin-MLL Interaction - The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes. | 2022-07-21 |
20220227787 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES - The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein. | 2022-07-21 |
20220227788 | PYRROLOPYRIMIDINE COMPOUND AND USE THEREOF - The present invention relates to a pyrrolopyrimidine compound used as a JAK inhibitor, and the use thereof in the preparation of a drug for treating a JAK1- and/or JAK2-associated disease, and in specifically relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof. | 2022-07-21 |
20220227789 | NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) - The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds. | 2022-07-21 |
20220227790 | NOVEL COMPOUNDS, FUNCTIONALISED DIOXABOROLANE OR DIOXABORINANE DERIVATIVES, METHOD FOR PREPARING SAME AND USES THEREOF - The invention relates to functionalised dioxaborolane or dioxaborinane derivatives of formula (I), wherein R | 2022-07-21 |
20220227791 | NOVEL ARGINASE INHIBITORS - The present invention relates to novel arginase inhibitors of formula (I). These novel compounds are useful in the treatment of diseases that are associated with arginase activity, such as asthma, allergic rhinitis and COPD (chronic obstructive pulmonary disease). | 2022-07-21 |
20220227792 | CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE AGENTS FOR BORON NEUTRON CAPTURE THERAPY - Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and (II) and pharmaceutically acceptable salt thereof: wherein the substituents are as described. | 2022-07-21 |
20220227793 | ZIRCONIUM-BASED METAL-ORGANIC FRAMEWORK MATERIAL AND PREPARATION METHOD THEREOF - Disclosed are a zirconium-based metal-organic framework material and a preparation method thereof. Plasma-activated water or strong acid electrolyzed water is added to a raw material system for preparing a zirconium-based metal-organic framework material UiO-66, and they are then subjected to a reaction to obtain a crude product. The crude product is subjected to a post-treatment to obtain the zirconium-based metal-organic framework material UiO-66. | 2022-07-21 |
20220227794 | PROGRAMMABLE POLYMERIC DRUGS - Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): | 2022-07-21 |
20220227795 | METHOD FOR MANUFACTURING ALKENYL PHOSPHORUS COMPOUND | 2022-07-21 |
20220227796 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF - The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. | 2022-07-21 |
20220227797 | TUNGSTEN IMIDO ALKYLIDENE O-BITET AND O-BINOL COMPLEXES AND USE THEREOF IN OLEFIN METATHESIS REACTIONS - The invention relates to tungsten imido alkylidene compounds bearing a ligand derived from a 1,1′-binaphthyl-2-ol or a 5,5′,6,6′,7,7′,8,8′-octahydro-1,1′-binaphthyl-2-ol which bind to tungsten in its olate-form via proton abstraction from the phenolic OH group. The complexes may be used in various olefinic metathesis reactions, preferably ethenolysis and cross-metathesis of unsaturated fatty acid esters, and ring-closing metathesis reactions. | 2022-07-21 |
20220227798 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT - A method is provided for manufacturing an aqueous formulation of a manganese-containing coordination complex, by combining a source of the manganese-containing coordination complex with a source of chloride anion in an aqueous solution, and simultaneously with or following combination of the source of chloride anion and the source of manganese-containing coordination complex in the aqueous solution, providing a source of a dianion to the aqueous solution to form the aqueous formulation. | 2022-07-21 |
20220227799 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Provided are compounds containing platinum which is coordinated by a tetradentate ligand wherein the tetradentate ligand comprises at least one five-membered ring comprising at least one nitrogen atom which is fused to a further five- or six membered ring. Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds. | 2022-07-21 |
20220227800 | IMPROVED PREPARATION OF CATALYST SYSTEM - Improved preparation process for silica supported catalyst systems, which comprise a specific class of metallocene complexes in combination with a boron containing cocatalyst and an aluminoxane cocatalyst and use of the new, improved catalyst system. | 2022-07-21 |
20220227801 | TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERS - A tetrasaccharide of formula I and a method of production thereof are provided. Furthermore, a conjugate comprising the tetrasaccharide and a molecule attached to the tetrasaccharide, preferably via its amine group, is also provided. Compositions, preferably immunogenic or vaccine compositions, comprising this tetrasaccharide or this conjugate are also provided. Such tetrasaccharides, conjugates, and compositions can be used for preventing or treating a disease caused by a | 2022-07-21 |
20220227802 | ANTIBACTERIAL AMINOGLYCOSIDE DERIVATIVES - Disclosed are a new class of antibacterial aminoglycoside derivatives, pharmaceutical compositions containing such compounds, and application thereof in the preparation of drugs for treating diseases related to bacterial infections. Specifically disclosed are a compound represented by formula (II), pharmaceutically acceptable salts thereof, and isomers thereof. | 2022-07-21 |
20220227803 | 4-THIORIBOSE NAD ANALOGUES AND METHODS OF SYNTHESIZING AND USING THE SAME - This disclosure provides a method of synthesis of 4′-thioribose NAD+ and analogues thereof, using an efficient chemoenzymatic approach. Also provided are methods of inhibiting the CD38 enzyme and compounds including 4′-thioribose NAD+ and compounds related thereto. | 2022-07-21 |
20220227804 | COMBINATION OF A POLYHYDROXYLATED BILE ACID AND A FARNESOID X RECEPTOR AGONIST - The present invention relates to, in part, a combination therapy of a polyhydroxylated bile acid and a farnesoid X receptor agonist. The present invention also provides, in part, a pharmaceutical composition comprising a farnesoid X receptor agonist and a polyhydroxylated bile acid in the preparation of a medicament for treating a biliary disorder or a gastrointestinal disorder. | 2022-07-21 |
20220227805 | METHODS OF PURIFYING CHARGE-SHIELDED FUSION PROTEINS - The present invention relates to method of purifying charge-shielded proteins from a cell lysate or periplasmic releasate using hydrophobic interaction chromatography as a first chromatography steps. Also provided herein are compositions comprising charge-shielded proteins and methods of treatment using purified charge-shielded proteins. | 2022-07-21 |
20220227806 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS - The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof. | 2022-07-21 |
20220227807 | BIOACTIVE PEPTIDES AND COMPOSITIONS COMPRISING THEM - The present invention relates to bioactive peptides and to the cosmeceutical compositions containing them, useful for the prevention and treatment of the signs of skin aging, such as wrinkles, fine lines and loss of firmness and elasticity of the skin, thanks to their efficacy in the protection of the dermal collagen. | 2022-07-21 |
20220227808 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF - Provided are cyclic peptide analogs, conjugates comprising such compounds, and pharmaceutical compositions comprising such compounds and conjugates, and methods of treating cancer with such compounds and conjugates. | 2022-07-21 |
20220227809 | NOROVIRUS-BINDING PEPTIDE - A peptide that specifically binds to norovirus, which is useful for detection and infection control of norovirus is provided. A norovirus-binding peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 327. | 2022-07-21 |
20220227810 | HEPARIN-BINDING CATIONIC PEPTIDE SELF-ASSEMBLING PEPTIDE AMPHIPHILES USEFUL AGAINST DRUG-RESISTANT BACTERIA - Disclosed are peptides comprising an amphiphilic backbone and a cationic heparin-binding motif peptide. The peptides can be used in methods of antimicrobial treatment. | 2022-07-21 |
20220227811 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES - The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer. | 2022-07-21 |
20220227812 | Treatments for Gastrointestinal Disorders - The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. | 2022-07-21 |
20220227813 | Ras INHIBITORY PEPTIDE - A cyclic peptide or a pharmaceutically acceptable salt of the cyclic peptide includes an amino acid sequence represented by a Formula: c[X | 2022-07-21 |
20220227814 | CYCLIC DOMINANT NEGATIVE COMPETENCE STIMULATING PEPTIDE ANALOGS AND METHODS OF TREATING STREPTOCOCCUS PNEUMONIAE INFECTIONS - Disclosed herein are compositions, methods of treatment and kits for treating | 2022-07-21 |
20220227815 | COMPOSITIONS AND METHODS USEFUL IN TREATING BRAIN DISEASES - Compounds, compositions, and methods are provided that are useful in treating brain diseases by effecting delivery across the blood brain barrier of molecules that otherwise do not (or insignificantly) pass across the blood brain barrier, where compounds of the present technology include but are not limited to cyclo(1,6)SHAVSS (“HAVN1”), cyclo(1,5)SHAVS (“HAVN2”), cyclo(1, 8)TPP V SHAV (“cyclic ADTHAV”), cyclo(1,6)ADTPPV (“ADTN1”), cyclo(1,5)DTPPV (“ADTN2”), acetyl-TPPVSHAV-NH2 (“linear ADTHAV”), and pharmaceutically acceptable salts thereof. | 2022-07-21 |
20220227816 | MODIFIED AAV CAPSIDS AND USES THEREOF - The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein that binds heparan sulfate proteoglycans, where the AAV virions exhibit greater infectivity of retinal cells, altered tropism and/or the ability to bind and cross the inner limiting membrane following intravitreal injection. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease. | 2022-07-21 |
20220227817 | ENGINEERED GLOBULAR ENDOLYSIN, A HIGHLY POTENT ANTIBACTERIAL ENZYME FOR MULTIDRUG RESISTANT GRAM-NEGATIVE BACTERIA - The subject invention pertains to lysins fused to a CeA peptide fragment, particularly at the C-terminus of the lysin. The subject invention also pertains to recombinant DNA encoding said lysins, vectors encoding said recombinant DNA, host cells comprising said vectors, and compositions comprising said lysins. The invention further pertains to a method of treating a bacterial infection, particularly a Gram-negative bacterial infection. | 2022-07-21 |
20220227818 | KLEBICINS FOR THE CONTROL OF KLEBSILELLA - The invention provides a protein having cytotoxic activity against | 2022-07-21 |
20220227819 | COMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASE - Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2022-07-21 |
20220227820 | RECOMBINANT GLYCAN BINDING PROTEINS - Aspects of the disclosure relate to compositions and methods for expressing glycan binding proteins (GBPs) in a cell or cells. In some embodiments, the disclosure provides recombinant Ab-Y3 protein variants and isolated nucleic acids engineered to express the same. In some embodiments, the disclosure provides methods of isolating, purifying, detecting, or screening for certain proteins (e.g., IgG proteins) using recombinant Ab-Y3 protein variants. | 2022-07-21 |
20220227821 | GENE LBA5 FOR REGULATING LATERAL SHOOT ANGLES, GROWTH HABITS, AND PLANT ARCHITECTURE OF ARACHIS HYPOGAEA L., AND USE THEREOF - A gene LBA5 for regulating lateral shoot angles, growth habits, and a plant architecture of | 2022-07-21 |
20220227822 | A POLYPEPTIDE AND RELATED PRODUCTS, METHODS AND USES - The invention relates to an isolated polypeptide encoded by Sghrt and related uses. In addition, methods of assessing a heart function, treating impaired heart function by inhibiting Sghrt, identifying a potential drug for treating impaired heart function, and dedifferentiating and/or proliferating a heart cell by inhibiting Sghrt are claimed. | 2022-07-21 |
20220227823 | MOLECULAR GUIDE SYSTEM PEPTIDES AND USES THEREOF - Disclosed are compositions comprising an antibody conjugated to one or more molecular guidance system (MGS) peptides. Disclosed are methods of treating a subject in need thereof comprising administering to the subject in need thereof an effective amount of an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target involved in the disease process. Disclosed are methods of targeting an intracellular target comprising administering an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target. | 2022-07-21 |
20220227824 | USE OF SRRD IN THE INHIBITION OF PROTEIN AGGREGATION - The present disclosure is directed to the use of SRR1 domain-containing protein (SRRD) or active fragment thereof to reduce protein aggregation, such as that occurring in neurodegenerative diseases. | 2022-07-21 |
20220227825 | FGF21 VARIANTS - The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis. | 2022-07-21 |
20220227826 | ENGINEERED FGF1 AND FGF2 COMPOSITIONS AND METHODS OF USE THEREOF - Engineered FGF1 and FGF2 polypeptides, polynucleotides encoding these polypeptides and DNA constructs, vectors and compositions including these engineered polypeptides are provided herein. The engineered FGF1 and FGF2 polypeptides are more stable than their wild-type counterparts and may be more effective at treating a variety of conditions that FGF1 and FGF2 are useful for treating such as wound healing. | 2022-07-21 |
20220227827 | PROTEINACEOUS HETERODIMER AND USE THEREOF - Proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof. | 2022-07-21 |
20220227828 | METHOD FOR OVEREXPRESSING IL-15 IN PORCINE SKELETAL MYOBLASTS AND USE THEREOF - The present disclosure relates to the field of genetic engineering, in particular to a method for overexpressing IL-15 in porcine skeletal myoblasts and use thereof. In the present disclosure, the porcine IL-15 gene is transferred into the lentiviral vector and then the lentiviral vector is transferred into the porcine skeletal myoblasts, so that IL-15 is successfully overexpressed in the porcine skeletal myoblasts. The method for overexpressing IL-15 provided by the present disclosure solves the problem that IL-15 needs to be added multiple times and the steps are complicated in the traditional research process. The present disclosure demonstrates that overexpression of IL-15 has a regulating effect on proliferation, cell apoptosis, anti-oxidation capacity of the porcine skeletal myoblasts, which charts a course for further study of IL-15. | 2022-07-21 |
20220227829 | IL-2 MUTANT PROTEIN PROLIFERATING IMMUNE CELLS - Provided in the present invention are an IL-2 mutant protein, a fusion protein or conjugate containing the IL-2 mutant protein, and a pharmaceutical composition containing the IL-2 mutant protein, fusion protein or conjugate. Compared with wild-type IL-2 protein, the IL-2 mutant protein of the present invention eliminates or reduces the affinity for a high-affinity IL-2 receptor and substantially retains the affinity for a medium-affinity IL-2 receptor. | 2022-07-21 |
20220227830 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF - The present disclosure provides GIP receptor agonist peptide compounds suitable for once per day dosing (QD), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by any of the formulas (I)-(V) or a salt thereof, and a medicament comprising the same are provided. | 2022-07-21 |
20220227831 | TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS - The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease. | 2022-07-21 |
20220227832 | PROTEASE-ACTIVATING CD45-GATE CAR - A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker. | 2022-07-21 |
20220227833 | CD80 VARIANT PROTEINS AND USES THEREOF - The present disclosure provides variant CD80 polypeptides that have altered affinity for their cognate binding partners, and immunomodulatory fusion proteins comprising the variant CD80 polypeptides. The present disclosure also provides pharmaceutical compositions comprising such polypeptides and/or proteins and methods for modulating immune responses and/or treatment of cancer, infectious diseases, and/or immunological diseases. | 2022-07-21 |
20220227834 | PHARMACEUTICAL FORMULATIONS CONTAINING CD80 EXTRACELLULAR DOMAIN-FC FUSION PROTEINS - The present disclosure provides pharmaceutical compositions comprising CD80 extracellular domain (ECD)-fragment crystallizable (Fc) fusion molecules. The present disclosure also provides methods for treating solid tumors by administering such pharmaceutical compositions. | 2022-07-21 |
20220227835 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME - The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions. | 2022-07-21 |
20220227836 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME - The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions. | 2022-07-21 |
20220227837 | IL-2 COMPOSITIONS AND METHODS OF USE THEREOF - Provided are activatable proproteins comprising at least two separate polypeptide chains, the first comprising IL-2 fused to a masking moiety and the second comprising an IL-2 binding protein fused to a masking moiety, and related pharmaceutical compositions and methods of use thereof. | 2022-07-21 |
20220227838 | COVALENT MODIFICATION OF BIOLOGICAL MACROMOLECULES - The present disclosure provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a biological macromolecule comprising one or more thiol groups; and (b) a molecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure also provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a molecule comprising one or more thiol groups; and (b) biological macromolecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure further provides a covalently modified biological macromolecule prepared by any of disclosed methods. The covalently modified biological macromolecules may be further crosslinked to form a scaffold. | 2022-07-21 |
20220227839 | COLLAGEN NANOPARTICLES FROM SCALY FISH SKIN - Disclosed are collagen nanoparticles obtained from waste scaly skins from fish by using a micro fluid technique, a method for obtaining the collagen nanoparticles, and their field of use. | 2022-07-21 |
20220227840 | ENGINEERED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND USES THEREOF - The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the C | 2022-07-21 |
20220227841 | Process for Preparing Immunoglobulin Compositions - A process for the preparation of pharmaceutically acceptable immunoglobulin compositions from plasma-derived immunoglobulin fractions which allows the parallel preparation of immunoglobulin compositions enriched in IgG, IgM and IgA. In this process, immunoglobulin contained in Cohn fraction I/II/III or Kistler Nitschmann fraction A+I is resolubilized at conductivities of at least 1 mS/cm, and following removal of contaminating protein the resolubilized immunoglobulin is subjected to anion exchange chromatography to obtain IgG- and IgM/IgA-enriched immunoglobulin compositions. The IgG-enriched immunoglobulin composition is further subjected to treatment with a cation exchange material to obtain an immunoglobulin composition having a reduced properdin content. | 2022-07-21 |
20220227842 | CLEAVING PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN - Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2. | 2022-07-21 |
20220227843 | CORONAVIRUS-BINDING MOLECULES AND METHODS OF USE THEREOF - The present invention provides binding molecules, including monoclonal antibodies, multi-specific antibodies, and antibody fragments, that specifically bind to the coronavirus, such as SARS-CoV-2, and methods of use thereof. In some aspects of the invention, the binding molecules are human antibodies, fragments, or derivatives thereof that specifically bind to SARS-CoV-2 spike protein. In some aspects of the invention, the binding molecules function to neutralize SARS-CoV-2. The present invention also relates to methods of using the binding molecules and compositions for diagnosis and treatment. | 2022-07-21 |
20220227844 | NEUTRALIZING ANTI-SARS-COV-2 ANTIBODIES - This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections. | 2022-07-21 |
20220227845 | Multispecific Anti-HIV Antibodies - The present invention provides a multispecific anti-HIV antibody that binds to multiple epitopes on HIV envelope protein, wherein the antibody comprises: i. an amino acid sequence that binds to a V1/V2 apex glycan epitope; ii. an amino acid sequence that binds to a V3-base glycan region epitope; iii. an amino acid sequence that binds to a CD4 binding site (CD4bs) epitope; iv. an amino acid sequence that binds to a gp120/gp41 interface epitope; and v. an amino acid sequence that binds to a membrane proximal external region (MPER) epitope. | 2022-07-21 |
20220227846 | ERADICATION OF BACTERIAL BIOFILM USING ANTI-AMYLOID MONOCLONAL ANTIBODIES - The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition. | 2022-07-21 |
20220227847 | HUMANIZED ANTIBODY - The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. | 2022-07-21 |
20220227848 | Type XXIII Collagen Assay - The present invention provides monoclonal antibodies that target collagen type XXIII, and to immunoassays and kits employing the antibodies for detecting and quantifying the epitope. The invention also provides a method for identifying and monitoring subjects with inflammatory bowel disease. | 2022-07-21 |
20220227849 | INHIBITOR OF SURFACE PROTEIN (SP-D) / SIRPA / SHP2 PATHWAY FOR USE IN THE PREVENTION AND/OR TREATMENT OF SECONDARY INFECTION - The invention relates inhibitor of surface protein D (SP-D) and/or inhibitor of SP-D-SIRPα interaction for use in the prevention and/or the treatment of secondary disease, in particular nosocomial disease. | 2022-07-21 |
20220227850 | BINDING MOLECULES - The disclosure relates to single domain antibodies that bind human serum albumin and methods for using such single domain antibodies to extend the half life of therapeutic molecules. | 2022-07-21 |
20220227851 | METHODS OF TREATING VITILIGO USING AN ANTI-C5 ANTIBODY - Provided are methods for clinical treatment of vitiligo using an anti-CS antibody or antigen binding fragment thereof. | 2022-07-21 |
20220227852 | APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF - Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE. | 2022-07-21 |
20220227853 | NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE - Antibodies and antigen binding fragments that specifically bind to | 2022-07-21 |
20220227854 | ANTI-ADRENOMEDULLIN (ADM) BINDER FOR USE IN THERAPY OR PREVENTION OF SYMPTOMS OF ILLNESS - Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy or to prevention of symptoms of illness and/or for use in therapy or prevention of diseases characterized by said symptoms. The symptoms of illness may be selected from the group of nausea, headache, muscle aches, back pain, shivering, vomiting in a subject wherein said antibody or fragment or scaffold may bind to ADM of amino acids 1 to 52 (SEQ ID NO: 1), or to fragments thereof. | 2022-07-21 |
20220227855 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES - Described herein is a method of treating a subject in need of treatment for pathological angiogenesis including administering to the subject a glycosaminoglycan linked either covalently or noncovalently to an anti-VEGF antibody, an anti-VEGF antibody fragment, an anti-VEGF protein, an anti-VEGF peptide, or an anti-VEGF aptamer. Also included is a glycosaminoglycan linked either covalently or noncovalently to an anti-VEGF antibody, an anti-VEGF antibody fragment, an anti-VEGF protein, an anti-VEGF peptide, or an anti-VEGF aptamer. | 2022-07-21 |
20220227856 | METHODS FOR TREATING IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNOSUPPRESSION - The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression. | 2022-07-21 |
20220227857 | NOVEL MODULATORS - Antibodies that modulate insulin receptor signaling are provided. | 2022-07-21 |
20220227858 | CONTROLLING OF IMMUNE ACTIVATION BY SOLUBLE CLEVER-1 - Altering levels of soluble CLEVER-1 in circulation achieves either immune activation or immune-suppression of T cells in an individual. Soluble CLEVER-1 has been found to bind to activated T cells using Receptor of Activated Protein C Kinase 1 (RACK1) as its ligand. | 2022-07-21 |
20220227859 | METHOD TO TREAT TYPE 2 INFLAMMATION OR MAST-CELL DEPENDENT DISEASE - The present invention relates to the treatment of type 2 inflammation or mast-cell dependent disease. The inventors showed that, when exposed to domestic allergic alarms, activation of TRPV1+Tac1+ nociceptor-MRGPRB2+ MC sensory clusters might represent a key early event controlling the development of frequent mast cell-dependent allergic disorders. The human ortholog of MRGPRB2 (MRGPRX2) can thus be a good target to treat type 2 inflammation or mast cell-dependent disorders. Thus, the present relates to a MRGPRX2 inhibitor for use in the treatment of a type 2 inflammation or mast cell-dependent disorders in a subject in need thereof. | 2022-07-21 |
20220227860 | TIGIT AND PD-1/TIGIT-BINDING MOLECULES - The present invention relates to polypeptide molecules that bind to human TIGIT, and to polypeptide molecules that bind to human PD-1 and human TIGIT, and are useful for treating solid tumors, alone and in combination with chemotherapy and/or ionizing radiation. | 2022-07-21 |
20220227861 | ANTI-MITOTIC COMPOSITION COMPRISING ANTIBODIES AGAINST ZIP6 AND/OR ZIP10 - The invention relates to an anti-mitotic agent comprising at least one antibody, or an epitope thereof, that selectively binds the extracellular domain of at least one ZIP (Zrt, Irt-like Proteins) transporter protein to inhibit its function, specifically mitosis; a composition comprising same; and the use of said anti-mitotic agent or composition to treat a hyper proliferative disorder including cancer. | 2022-07-21 |
20220227862 | TREATMENT OF B CELL MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI CD20 ANTIBODIES OR CHEMOTHERAPEUTICS - The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL). | 2022-07-21 |
20220227863 | ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES - Disclosed herein are anti-immunoglobulin-like transcript-3 (ILT3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. | 2022-07-21 |
20220227864 | BIOLOGICAL BINDING MOLECULES - The invention relates to the field of the preparation, identification and selection of biological binding molecules such as antibodies or fragments thereof, and also the use thereof in the context of therapy and prophylaxis of cancers, such as malignant B-cell neoplasia in particular. The binding molecules are capable of selectively binding to B-cell receptors that have a light chain according to SEQ ID NO. 18. | 2022-07-21 |